Cancer Biomarkers

作者资格政策规定AI聊天机器人（如ChatGPT）不应被列为作者，作者资格标准、通讯作者人选等信息详见相关作者资格政策。 模型中文摘要

Please view our authorship policies, which includes information on criteria for authorship, who should be the corresponding author and more. Please note that AI chatbots, for example ChatGPT, should not be listed as authors. For more information see the policy on Use of ChatGPT and generative AI tools.

期刊鼓励作者在合适的伦理和法律前提下，将研究数据存入相关公共数据存储库，提供链接数据的数据可用性声明；若无法共享数据，应在声明中说明原因，并在研究中引用该数据。 模型中文摘要

The Journal is committed to facilitating openness, transparency and reproducibility of research, and has the following research data sharing policy. For more information, including FAQs please visit the Sage Research Data policy pages. Subject to appropriate ethical and legal considerations, authors are encouraged to: Share your research data in a relevant public data repository Include a data ava…

作者应在指定标题下提供伦理批准声明，即使方法部分已包含相关信息；若无需伦理批准，须明确说明；涉及人类参与者、人类数据或人体组织的研究必须声明相关伦理委员会或机构审查委员会批准或豁免批准，并提供委员会全名、所属机构及批准号。 模型中文摘要

Please include your ethics approval statements under this heading, even if you have already included ethics approval information in your methods section. If ethical approval was not required, you need to explicitly state this. All papers reporting studies involving human participants, human data or human tissue must state that the relevant Ethics Committee or Institutional Review Board approved th…

该期刊为开放获取、同行评审期刊，所有被接受的文章在出版后立即免费在线发布，采用知识共享许可并永久在线托管；同行评审通过后需支付一次性文章处理费（APC）3200美元，由资助方、机构或作者支付，提交稿件本身不收费。 模型中文摘要

Cancer Biomarkers is an open access, peer-reviewed journal. All accepted articles are made freely available online immediately upon publication, are published under a Creative Commons license, and hosted online in perpetuity. If, after peer review, your manuscript is accepted for publication, a one-time article processing charge (APC) is payable to cover the cost of publishing, paid by the funder,…

该期刊采用单盲同行评审，审稿人与编辑互动，不公布审稿信息；稿件先经初步评估，不符合指南要求的稿件将被退回修改，超出范围或不合适的稿件可能未经同行评审即被直接拒稿，通过初步评估后进入同行评审。 模型中文摘要

The following summary describes the peer review process for this journal: Identity transparency: Single-anonymized Reviewer interacts with: Editor Review information published: None Your manuscript will undergo an initial evaluation. If it does not conform to the requirements laid out in these guidelines, it will be returned to you for amendments prior to peer review. Manuscripts may be desk rejec…

期刊和Sage非常重视版权侵权、抄袭或其他违反出版最佳实践的行为，请阅读Sage关于抄袭的完整政策及可能采取的措施。 模型中文摘要

The journal and Sage take issues of copyright infringement, plagiarism or other breaches of best practice in publication very seriously. Please read Sage's complete policy on plagiarism and the actions we may take.

期刊接受已在预印本服务器上发布的稿件，投稿时须在指定字段填写预印本DOI，并建议在投稿时告知编辑部；同行评审期间不应在预印本服务器上发布更新版本。 模型中文摘要

The journal will consider submissions of manuscripts that have been posted on preprint servers. Please enter the preprint DOI in the designated field when submitting your manuscript. We advise that you inform the Journal Editorial office about your posted preprint at submission. Note that you should not post an updated version of your manuscript on a preprint server while it is being peer reviewed…

期刊认可ICMJE要求，临床试验须在首次招募参与者时或之前在WHO认可的公共试验注册机构注册；根据AllTrials运动，若迟注册理由可接受，回顾性注册的试验也将被考虑；试验注册机构名称、网址及注册号必须列在摘要末尾。 模型中文摘要

The journal endorses the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first participant enrollment. However, consistent with the AllTrials campaign, retrospectively registered trials will be considered if the justification for late registration is acceptable. The trial registry name and URL, and registration number must be …